Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $328005.0.

  • Evoke Pharma's Change in Accured Expenses rose 9898.75% to $328005.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 66526.54%. This contributed to the annual value of $751754.0 for FY2024, which is 1474.95% up from last year.
  • Evoke Pharma's Change in Accured Expenses amounted to $328005.0 in Q3 2025, which was up 9898.75% from $1.7 million recorded in Q2 2025.
  • Evoke Pharma's 5-year Change in Accured Expenses high stood at $1.7 million for Q2 2025, and its period low was -$1.1 million during Q1 2024.
  • Over the past 5 years, Evoke Pharma's median Change in Accured Expenses value was $159916.0 (recorded in 2024), while the average stood at $132337.3.
  • Within the past 5 years, the most significant YoY rise in Evoke Pharma's Change in Accured Expenses was 102257.79% (2024), while the steepest drop was 52053.83% (2024).
  • Evoke Pharma's Change in Accured Expenses (Quarter) stood at $307773.0 in 2021, then tumbled by 128.07% to -$86378.0 in 2022, then soared by 322.27% to $191996.0 in 2023, then soared by 673.52% to $1.5 million in 2024, then tumbled by 77.91% to $328005.0 in 2025.
  • Its Change in Accured Expenses stands at $328005.0 for Q3 2025, versus $1.7 million for Q2 2025 and -$493918.0 for Q1 2025.